Why the study?
Data are conflicting regarding outcomes across varying body mass index (BMI) in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants.
Does varying body mass index affect mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants?
Population
26 047 non-vitamin K oral anticoagulant-treated patients with atrial fibrillation
Comparison
Outcomes compared across continuous BMI and BMI categories from underweight to obesity class III
Design
Registry-based observational cohort study
Key result
In NOAC-treated patients with atrial fibrillation, both underweight (HR 1.77; 95% CI 1.57-1.99) and obesity class III (HR 1.67; 95% CI 1.40-1.99) were associated with increased mortality.
Authors
Loading...
May support BMI-stratified monitoring in NOAC-treated AF without altering therapy; leaves open causal mechanisms and prospective validation.
Cohort (n=26,047)
Does varying body mass index affect mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants?
Effect estimate: HR 1.77 (95% CI 1.57-1.99)
In atrial fibrillation patients treated with non-vitamin K oral anticoagulants, there is a U-shaped relationship between BMI and both mortality and major bleeding, with the highest risks observed in underweight and class III obesity patients.
Hansson et al. (2023) conducted a cohort in Atrial fibrillation (n=26,047). Varying Body Mass Index (BMI) vs. Normal weight (18.5 to <25 kg/m2) was evaluated on Mortality, ischemic stroke/systemic embolism, and major bleeding (HR 1.77, 95% CI 1.57-1.99). In NOAC-treated patients with atrial fibrillation, both underweight (HR 1.77; 95% CI 1.57-1.99) and obesity class III (HR 1.67; 95% CI 1.40-1.99) were associated with increased mortality.